India

COVID-19 Coronavirus Pandemic – Latest Media Coverage

Novavax COVID-19 vaccine

Vaccine against COVID-19

Novavax COVID-19 vaccine ▸ Facts ▸ Comments ▸ News ▸ Videos

Novavax COVID-19 vaccine: Vaccine against COVID-19

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

0 shares	Share Tweet Save Post Send

You Might Like

Covovax for adults to reach metros in a week: SII Serum Institute of India’s CEO Adar Poonawalla told TOI on Friday that doses of Covovax — Covid booster shot for adults — would reach major cities in four to five days, while a Bharat Biotech.. IndiaTimes - Published on April 14, 2023
Serum Institute of India restarts manufacturing of Covid-19 vaccine Covishield Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the.. IndiaTimes - Published on April 12, 2023
Covid-19: CoWIN to soon offer Covovax as booster shot, priced at Rs 225 per dose Covovax approved as booster dose for adults on CoWIN portal in India. DNA - Published on April 10, 2023

Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per dose Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax.. IndiaTimes - Published on April 10, 2023
Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults IndiaTimes - Published on April 3, 2023
Covid vaccine news: SII's Covovax approved as heterologous booster dose for adults DCGI has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults. DNA - Published on January 16, 2023

Drug panel favours nod for Covovax as Covid booster An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have.. IndiaTimes - Published on January 12, 2023
Covid wrap: Govt panel for Covovax jab as heterologous booster dose; worry in China over post-holiday surge among elderly IndiaTimes - Published on January 12, 2023
Covovax may get approval as heterologous booster The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for.. IndiaTimes - Published on January 10, 2023
Covovax vaccine to get booster dose approval in 10-15 days: SII CEO Adar Poonawalla IndiaTimes - Published on January 9, 2023